Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01336907|
Recruitment Status : Withdrawn (never started)
First Posted : April 18, 2011
Last Update Posted : September 21, 2016
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD). However, the device has the ability to detect the development of the lesion post treatment and therefore to assess in determination of the next treatment.
The Optical Coherence Tomography (OCT) may be used as well to identify choroidal neovascularization (CNV). Comparison between the two methods will allow better understanding of both devices.
The FORESEE HOME can be used as an assessment tool for the progression and success of the treatment given to AMD lesions. Therefore, evaluating the size and the location of the treated lesions may serve as an additional tool.
|Condition or disease|
|Age Related Macular Degeneration Choroidal Neovascularization|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Comparison Between Home Macular Perimeter and OCT Visual Field Defects in Patients With CNV|
naive CNV subjects
Newly diagnosed CNV, before any treatment (naïve)
previously diagnosed CNV subjects
Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
- Investigate the correlation between features of CNV lesions as measured with SD OCT and in the ForeseeHome. [ Time Frame: 3-4 months ]the measures are Height of Pigment Epithelial Detachment , Sub Retinal Fluid Thickness , Maximum Diameter of Largest Retinal Cyst , Maximum Retinal Thickness , Central Retinal Thickness
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01336907
|Centre Hospitalier Intercommunal de Creteil|
|Principal Investigator:||Giuseppe Querques, Dr.||Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil, University Paris XII, Paris, France|